Ruoheng Wei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ruoheng Wei has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- A. David Burden
Institute of Infection, Immunity and Inflammation University of Glasgow Glasgow UK
1 shared publication Ali Alsharqi
Dermatology Department Royal Liverpool and Broadgreen University Hospital Trust Liverpool UK
1 shared publicationAlice Russell
St John's Institute of Dermatology, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine King's College London London UK
1 shared publication- Andrew Wright
Centre for Skin Sciences University of Bradford Bradford UK
1 shared publication - Angela Pushpa‐Rajah
St John's Institute of Dermatology, School of Basic & Medical Biosciences, Faculty of Life Sciences & Medicine King's College London London UK
1 shared publication - Annick de Vries
Sanquin Diagnostic Services Amsterdam The Netherlands
1 shared publication
Latest Publications
- Open Access
- 30 April 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (5) , e70563
Evaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study
Using a real‐world psoriasis cohort, we established the pharmacokinetic‐pharmacodynamic (PKPD) relationship for the biologic therapy adalimumab and evaluated the clinical utility and cost‐effectiveness of a proactive therapeutic drug monitoring (TDM) strategy. A total of 543 patients on adalimumab monotherapy for psoriasis provided 946 pharmacokinetic samples and 1700 Psoriasis Area Severity Index (PASI) disease severity measurements. To describe the PASI change over time, a one‐compartment linear PK model with first‐order absorption and elimination was linked to a turnover mechanism of skin lesions. Based on the PKPD relationship and a predefined therapeutic range, real‐time stochastic simulation was performed for a proactive TDM strategy, where trough levels guided dose escalation or reduction. Compared to the standard care, the TDM strategy improved PASI90 and PASI75 by 37.5% and 12.8%, respectively, with a 25.9% increase in drug costs. In the future, incorporating the PKPD model into a Bayesian therapeutic monitoring algorithm could facilitate individualized adalimumab dosing.
- 30 April 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (5) , e70563
Open AccessEvaluation of a Therapeutic Drug Monitoring Strategy for Adalimumab in Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study
Using a real‐world psoriasis cohort, we established the pharmacokinetic‐pharmacodynamic (PKPD) relationship for the biologic therapy adalimumab and evaluated the clinical utility and cost‐effectiveness of a proactive therapeutic drug monitoring (TDM) strategy. A total of 543 patients on adalimumab monotherapy for psoriasis provided 946 pharmacokinetic samples and 1700 Psoriasis Area Severity Index (PASI) disease severity measurements. To describe the PASI change over time, a one‐compartment linear PK model with first‐order absorption and elimination was linked to a turnover mechanism of skin lesions. Based on the PKPD relationship and a predefined therapeutic range, real‐time stochastic simulation was performed for a proactive TDM strategy, where trough levels guided dose escalation or reduction. Compared to the standard care, the TDM strategy improved PASI90 and PASI75 by 37.5% and 12.8%, respectively, with a 25.9% increase in drug costs. In the future, incorporating the PKPD model into a Bayesian therapeutic monitoring algorithm could facilitate individualized adalimumab dosing.